Trump White House Pulls Heidi Overton’s FDA Nomination

The White House withdrew Dr. Heidi Overton’s nomination to lead the FDA before a scheduled Senate committee vote, as Republican support remained uncertain and senators pressed for commitments on health policy.
President Donald Trump’s White House withdrew Dr. Heidi Overton’s nomination to lead the Food and Drug Administration on Tuesday, November 17, one day before the Senate health committee was scheduled to decide whether to send her nomination to the full Senate.
A White House official confirmed the decision to NBC News, while the Associated Press reported that the administration acted amid signs that Overton might not have enough support for confirmation. The withdrawal leaves the FDA without a permanent commissioner and gives the administration a narrow window to choose another candidate before control of the Senate changes in January.
Republican support remained unsettled
Overton needed support from Republicans on the Senate Health, Education, Labor and Pensions Committee because Democrats were expected to oppose her. Several Republican senators had not publicly committed to voting for her before the planned Wednesday committee meeting.
Committee Chairman Bill Cassidy of Louisiana, a physician, had publicly questioned whether Overton had the managerial background to run the agency and pressed her about scientific independence. The Associated Press reported that Cassidy had also criticized her support for breaking apart combination vaccines, including the measles, mumps and rubella vaccine. Senators Susan Collins of Maine and Lisa Murkowski of Alaska had also withheld firm support, according to NBC News.
After the nomination was pulled, Cassidy said his discussions with Overton had persuaded him that she would follow scientific evidence and resist decisions that could endanger public health. He said he believed a confirmation path still existed. Cassidy attributed the final dispute to requests from anti-abortion senators for additional administration commitments on what he called “life issues,” rather than to the vaccine questions that had shadowed the nomination.
FDA policy disputes shaped the hearing
Overton faced questions during her September confirmation hearing about whether she would act independently of Trump and Health and Human Services Secretary Robert F. Kennedy Jr. The agency is conducting a safety review of mifepristone, the medication used in most U.S. abortions, and has said it expects to report its findings by March. Murkowski criticized Overton at the hearing for not giving a clear position on access to the drug, NBC News reported.
Other concerns crossed factional lines within Trump’s coalition. Some senators focused on vaccines and the FDA’s authorization of fruit-flavored vaping products. Figures associated with the Make America Healthy Again movement, meanwhile, accused Overton and other White House officials of obstructing parts of Kennedy’s agenda. Those disputes made the nomination a test of whether a White House policy adviser could satisfy both Senate health-policy skeptics and competing groups inside the administration’s political base.
Who Overton is and what happens next
Overton is a physician specializing in preventive medicine and a White House domestic policy adviser. Before joining the administration, she served as chief policy officer at the America First Policy Institute, a conservative organization aligned with Trump. The president nominated her in August after Dr. Marty Makary left the commissioner’s post in May.
The agency is being led on an acting basis by Kyle Diamantas, an attorney who previously served as the FDA’s top food official. The White House did not immediately identify another nominee, according to the Associated Press. Any replacement would face a compressed confirmation schedule before Democrats take control of the Senate in early January; a nominee not confirmed during the current Congress would need to be nominated again.
The withdrawal is not a Senate rejection of Overton, because the committee did not hold its scheduled vote. It is instead an administration decision made after weeks of uncertainty about the votes and policy assurances needed to advance her nomination. The immediate result is continued interim leadership at the federal agency responsible for regulating medicines, vaccines, medical devices, tobacco products and much of the nation’s food supply.